

Structural Basis for the Inefficient Nucleotide Incorporation Opposite Cisplatin-DNA Lesion by Human DNA Polymerase β^*

Received for publication, August 16, 2014, and in revised form, September 16, 2014. Published, JBC Papers in Press, September 18, 2014, DOI 10.1074/jbc.M114.605451

Myong-Chul Koag, Lara Lai, and Seongmin Lee¹

From the Division of Medicinal Chemistry, College of Pharmacy, The University of Texas, Austin, Texas 78712

Background: Pol β has been shown to accurately but slowly incorporate nucleotide opposite the cisplatin-1,2-d(GpG) (Pt-GG) cross-link; however, its structural basis is unknown.

Results: Both guanines of the Pt-GG form Watson-Crick base pairing with the primer terminus dC and incoming dCTP.

Conclusion: Pol β accommodates the Pt-GG adduct with a semiopen conformation.

Significance: Our studies explain why pol β is less efficient at bypassing the Pt-GG than pol η .

Human DNA polymerase β (pol β) has been suggested to play a role in cisplatin resistance, especially in pol β -overexpressing cancer cells. Pol β has been shown to accurately albeit slowly bypass the cisplatin-1,2-d(GpG) (Pt-GG) intramolecular cross-link *in vitro*. Currently, the structural basis for the inefficient Pt-GG bypass mechanism of pol β is unknown. To gain structural insights into the mechanism, we determined two ternary structures of pol β incorporating dCTP opposite the templating Pt-GG lesion in the presence of the active site Mg²⁺ or Mn²⁺. The Mg²⁺-bound structure shows that the bulky Pt-GG adduct is accommodated in the pol β active site without any steric hindrance. In addition, both guanines of the Pt-GG lesion form Watson-Crick base pairing with the primer terminus dC and the incoming dCTP, providing the structural basis for the accurate bypass of the Pt-GG adduct by pol β . The Mn²⁺-bound structure shows that pol β adopts a catalytically suboptimal semiclosed conformation during the insertion of dCTP opposite the templating Pt-GG, explaining the inefficient replication across the Pt-GG lesion by pol β . Overall, our studies provide the first structural insights into the mechanism of the potential pol β -mediated cisplatin resistance.

Cisplatin (*cis*-diamminedichloroplatinum(II)) and its related platinum-based chemotherapeutic agents are widely used in the treatment of various human malignancies including testicular, ovarian, cervical, and non-small cell lung cancers (Fig. 1). Cisplatin is activated via intracellular aquation to form *cis*-[(NH₃)₂PtCl(OH₂)]⁺ and *cis*-[(NH₃)₂Pt(OH₂)₂]²⁺ (1). The aquated cisplatin species are potent electrophiles and react with the nucleophilic N7 atoms of purines in DNA to produce a cisplatin-1,2-d(GpG) (Pt-GG² hereafter) intramolecular cross-

link as the major cytotoxic lesion. The bulky cisplatin-DNA adducts can block DNA replication and transcription, thereby triggering cell cycle arrest and apoptosis of rapidly dividing cancer cells (1). The major limitation to cisplatin-based chemotherapy is cisplatin resistance, which arises from various mechanisms including uptake/efflux, nucleotide excision repair, and translesion bypass by DNA polymerases (2). The Y-family human DNA polymerase η (pol η) efficiently replicates across the bulky Pt-GG lesion and has been implicated in the accurate bypass of the Pt-GG lesion *in vivo* (3, 4).

Several reports suggest that the X-family human DNA polymerase β (pol β) may play a role in cisplatin resistance. Pol β has been shown to accurately bypass the Pt-GG cross-links *in vitro* (5) and to extend DNA chains of DNA polymerases α , δ , and ϵ that are stalled by the Pt-GG adducts (6). It has been suggested that pol β may contribute to cisplatin resistance in pol β -overexpressing cancer cells (7–9). Overexpression of pol β has been shown to facilitate translesion synthesis of the Pt-GG adduct and increase cisplatin resistance *in vivo* (10–14). Interestingly, pol β inserts dCTP opposite the Pt-GG adduct with an efficiency of ~2% relative to unmodified DNA, whereas pol η inserts the nucleotide opposite the lesion with an efficiency of ~40% relative to unmodified DNA (5, 15), indicating that the X-family DNA polymerase is much less efficient at replicating across the Pt-GG lesion than the Y-family DNA polymerase.

Several crystal structures of pol η and DNA polymerase IV (Dpo4) complexed with the Pt-GG-containing DNA have revealed the mechanisms for the accurate and efficient bypass of the Pt-GG lesion by the Y-family DNA polymerases (16–20), providing mechanistic insights into DNA polymerase-mediated chemoresistance to the platinum anticancer drugs. The structural basis for the accurate but inefficient catalysis across the Pt-GG lesion by the X-family DNA polymerase pol β is currently unknown. Herein, we report two crystal structures of pol β incorporating a non-hydrolyzable dCTP analog opposite the 5'-dG of the templating Pt-GG in the presence of the active site Mg²⁺ or Mn²⁺. These structures provide insights into the mechanism of the accurate but slow bypass of the Pt-GG by pol β . These structures also explain why the X-family DNA polymerase pol β is much less efficient at catalyzing through the bulky Pt-GG adducts than the Y-family DNA polymerase pol η .

* This work was supported by the College of Pharmacy at the University of Texas at Austin and Cancer Prevention and Research Institute of Texas Grant RP130219.

The atomic coordinates and structure factors (codes 4TUP, 4TUQ, 4TUR, and 4TUS) have been deposited in the Protein Data Bank (<http://www.pdb.org/>).

¹ To whom correspondence should be addressed. Tel.: 512-471-1785; Fax: 512-471-4726; E-mail: SeongminLee@austin.utexas.edu.

² The abbreviations used are: Pt-GG, cisplatin-1,2-d(GpG); pol, polymerase; Dpo4, DNA polymerase IV; dCTP* or dCMPNPP, 2'-deoxycytidine 5'-[(α,β)-imido]triphosphate; dUMPNPP, 2'-deoxyuridine 5'-[(α,β)-imido]triphosphate; dAMP CPP, α,β -methylene-dATP; r.m.s.d., root mean square deviation.

Pol β Catalysis across the Major Cisplatin-DNA Adduct




FIGURE 1. Chemical structures of platinum anticancer drugs.

EXPERIMENTAL PROCEDURES

DNA Sequences Used for X-ray Crystallographic Studies—The oligonucleotides used for the crystallographic studies were obtained from Integrated DNA Technologies (Coralville, IA). The template DNA sequence used for co-crystallization was 5'-CCCACGGCCCATCACC-3' (GG denotes the modification site for the Pt-GG cross-link). The upstream primer sequence was 5'-GGTGATGGGC-3'. The downstream primer sequence was 5'-phosphate-GTGGG-3'. The platinum-modified template was prepared following published procedures (21). In brief, cisplatin (8.3 mM in H₂O) was activated by adding 2 molar eq of silver nitrate and incubating the mixture in the dark at room temperature for 14–16 h. The reaction mixture was centrifuged at 13,000 $\times g$ for 20 min to collect the supernatant. The unmodified template DNA (1.5 μ mol) in 10 mM sodium phosphate buffer, pH 6.8 was mixed with the activated cisplatin (1.7 μ mol), and the mixture was incubated at 37 $^{\circ}$ C for 14–16 h. The Pt-GG-containing template DNA was purified by ion exchange column (Mono Q 5/50 GL, GE Healthcare) using a gradient from 0.1 to 1.0 M NaCl in 10 mM Tris buffer, pH 8.0. The site-specifically platinated template DNA was desalted using Sep-Pak C₁₈ cartridges (Waters) and dried under reduced pressure. The dried Pt-GG template DNA was reconstituted in water and annealed with upstream and downstream primers to give a single nucleotide gapped DNA as described previously (22).

Steady-state Kinetics of Single Nucleotide Incorporation Opposite the Templating Pt-GG by Pol β —Steady-state kinetic parameters were determined using the conditions described previously (23). Oligonucleotides used for kinetic assays (upstream primer, 5'-FAM (fluorescein amidite)-ATGGGGTTGATGTGC-3'; downstream primer, 5'-phosphate-GTAGGGATGTTTGGG-TAG-3'; and template, 5'-CTACCCAAACATCCCTACGGC-CATCAACTCCAT-3' where GG denotes the site of cisplatin modification) were purchased from Integrated DNA Technologies. The cisplatinated template was prepared using the method described above. To prepare DNA substrate containing a single nucleotide gap opposite the Pt-GG, the template, upstream primer, and downstream primer were annealed in hybridization buffer containing 10 mM Tris-HCl, pH 7.5 and 1 mM EDTA. Polymerase activities were determined using reaction mixtures containing 50 mM Tris-HCl, pH 7.5, 100 mM KCl, 5 mM MgCl₂ or MnCl₂, 80 nM single nucleotide gapped DNA, and various concentrations of incoming dCTP. To avoid product inhibition or substrate depletion that could interfere with initial velocity measurements, the pol β concentrations and reaction time intervals were adjusted for every experiment to ensure that the insertion product yield was less than 20%. The polymerase reactions were initiated by adding the enzyme to the single nucleotide gapped DNA substrate at 37 $^{\circ}$ C and stopped by adding a stop solution containing 95% formamide, 20

mM EDTA, 45 mM Tris borate, 0.1% bromphenol blue, and 0.1% xylene cyanol. The quenched reaction mixtures were separated on 20% denaturing polyacrylamide gels. The gels were analyzed using a PhosphorImager to quantify product formation. The k_{cat} and K_m were determined by fitting reaction rates over dCTP concentrations to the Michaelis-Menten equation. Each experiment was repeated three times. The efficiency of nucleotide insertion was calculated as k_{cat}/K_m . The relative efficiency of dCTP incorporation opposite the Pt-GG was determined as $f = (k_{\text{cat}}/K_m)_{[\text{dC:Pt-GG}]} / (k_{\text{cat}}/K_m)_{(\text{dC:dG})}$.

Co-crystallization of the Pol β :GG-dCTP and Pol β :Pt-GG-dCTP Ternary Complexes—Pol β was prepared with minor modifications of the method described previously (22). The binary pol β complex with the templating GG or Pt-GG in a single nucleotide gapped DNA was prepared by methods described previously (22). To prepare a pol β ternary complex with an incoming nucleotide opposite the templating unmodified GG or the Pt-GG, non-hydrolyzable dCMPNPP (dCTP*; 5 mM; Jena Biosciences) was added to the mixture of the pol β single nucleotide gapped binary complex. The ternary pol β -DNA complex co-crystals with dCMPNPP, paired with the templating dG, were grown by sitting drop vapor diffusion at 22 $^{\circ}$ C over several weeks in a buffer solution containing 50 mM imidazole, pH 7.5, 14–23% PEG3400, 20 mM divalent metal ions (MgCl₂ or MnCl₂), and 350 mM sodium acetate. The pol β :DNA co-crystals were cryoprotected with 50 mM Tris, pH 7.5, 14–23% PEG3400, 12% ethylene glycol, and 350 mM sodium acetate and flash frozen in liquid nitrogen. Diffraction data were collected at 100 K at the beamline 5.0.3 at the Advanced Light Source, Lawrence Berkeley National Laboratory. All diffraction data were processed using HKL 2000. The co-crystal structures were determined by molecular replacement (24) with a gapped binary complex structure (Protein Data Bank code 1BPX) and a ternary complex structure (Protein Data Bank code 1BPY) as the search models (25). The initial model was built using Coot (26) and refined using CCP4 (27). Ramachandran plots were obtained using MolProbity (28). All the crystallographic figures were generated using the molecular graphics program PyMOL (Schrödinger, LLC).

RESULTS AND DISCUSSION

We co-crystallized a ternary complex of pol β incorporating a non-hydrolyzable dCTP analog dCMPNPP (dCTP* hereafter) opposite the templating 5'-dG of the Pt-GG lesion in the presence of Mg²⁺ (Fig. 2). The non-hydrolyzable dCTP* was used for the crystallographic studies because it is isosteric to dCTP and coordinates with the active site metal ion in a manner comparable with that of the natural nucleotide (29). Non-hydrolyzable nucleotide analogs such as dUMPNPP (dUTP*) and dAMPNPP have been shown to tightly bind the pol β active site (29, 30), and the use of these analogs does not significantly alter the active site conformation of a pol β ternary complex (29, 31). The dNTP* analogs have been used to obtain ternary complex structures of various DNA polymerases (17, 32, 34, 35) including pol η in complex with cisplatin- and phenanthriplatin-modified DNA (32, 35). Unfortunately, our extensive efforts to crystallize a ternary complex of pol β incorporating dCTP* opposite the templating 3'-dG of the Pt-GG lesion failed.




FIGURE 2. Structures of the non-modified GG and the Pt-GG-Mg²⁺ complexes. *A*, overall structure of the unmodified GG gapped binary complex (Protein Data Bank code 4TUP). The template and primer strands are shown in yellow and orange, respectively. The α -helix N that contains the minor groove recognition amino acids is shown in red. The two guanines modified by cisplatin are shown in magenta. The primer terminus dC is shown in green. *B*, overall structure of the unmodified GG-dCTP* ternary complex (Protein Data Bank code 4TUQ). The incoming non-hydrolyzable dCTP* is shown in green. The active site Mg²⁺ ions are shown in green spheres. *C*, overall structure of the Pt-GG-dCTP*-Mg²⁺ ternary complex (Protein Data Bank code 4TUR). *D*, DNA sequences used for crystallographic studies. The site opposite the 5'-dG of the Pt-GG is indicated by an arrow. *E*, active site of the GG gapped binary complex structure. The distance between N2 of the templating dG and the α -helix N is indicated. *F*, active site of the GG-dCTP* ternary complex structure. The distance between N2(5'-dG) and N2(3'-dG) is indicated. *G*, active site of the Pt-GG-dCTP*-Mg²⁺ ternary complex structure. Platinum and NH₃ of the Pt-GG lesion are shown in gray and blue spheres, respectively. The cisplatin of the GG increases the distance between N2(5'-dG) and N2(3'-dG).

For comparison, we determined crystal structures of a single nucleotide gapped binary complex and a ternary complex with the templating GG-containing DNA (Fig. 2*D*). As expected, the overall structures of the gapped binary GG complex and the ternary GG-dCTP* complex are essentially identical to those of the published gapped binary and ternary pol β complexes, respectively (Fig. 2, *A* and *B*; see Table 1 for refinement statistics) (31). The root mean square deviation (r.m.s.d.) between our GG-dCTP* ternary complex (Protein Data Bank code 4TUQ) and the published GG-dCTP* ternary complex (Protein Data Bank code 4KLE (31)) is 0.325 Å, indicating that pol β ternary structures are not sequence-dependent. The unmodified GG gapped binary complex adopts an open protein conformation where the α -helix N that contains the minor groove edge recognition amino acids is ~ 10 Å away from the active site (Fig. 2*E*). The incorporation of dCTP opposite the templating unmodified dG induces a large conformational change of the protein to form the GG-dCTP* ternary complex with a closed protein conformation where the replicating base pair is sandwiched between the primer terminus base pair and the α -helix N (Fig. 2*F*). In contrast, the Pt-GG-dCTP*-Mg²⁺ ternary com-

plex structure, refined to 2.2-Å resolution, shows that the incorporation of dCTP opposite the templating 5'-dG of the Pt-GG induces only a minor conformational change in the protein. The Pt-GG-dCTP*-Mg²⁺ complex adopts a “semiopen” protein conformation (Fig. 2, *C* and *G*) where the α -helix N shifts toward the active site ~ 2 Å relative to the position observed in the GG gapped binary structure. The Pt-GG-dCTP*-Mg²⁺ ternary complex is structurally more similar to the unmodified GG binary complex (r.m.s.d. = 0.556 Å) than the GG-dCTP* ternary complex (r.m.s.d. = 1.396 Å; see Fig. 3*E*).

The Pt-GG-dCTP*-Mg²⁺ ternary complex structure explains why pol β accurately but slowly incorporates nucleotide opposite the bulky Pt-GG intrastrand cross-link adduct (Fig. 3). The DNA-distorting Pt-GG lesion is located in an open region and is accommodated in the pol β active site without any steric clashes with the protein (Fig. 3, *A* and *B*). The conformational perturbation of DNA caused by the Pt-GG lesion is mainly confined to the primer terminus and the replicating base pairs (Fig. 3, *C* and *E*), which have a large roll angle ($\sim 60^\circ$) and an increased distance between N2 of 3'-dG and N2 of 5'-dG (7.6 Å) compared with that in the unmodified complex (3.8 Å). The

Pol β Catalysis across the Major Cisplatin-DNA Adduct

TABLE 1
Data collection and refinement statistics

Protein Data Bank code	GG gapped binary 4TUP	GG·dCTP Mg ²⁺ ternary 4TUQ	Pt-GG·dCTP Mg ²⁺ ternary 4TUR	Pt-GG·dCTP Mn ²⁺ ternary 4TUS
Data collection				
Space group	<i>P</i> ₂ ₁	<i>P</i> ₂ ₁	<i>P</i> ₂ ₁	<i>P</i> ₂ ₁
Cell constants				
<i>a</i> (Å)	54.354	50.820	54.785	54.878
<i>b</i> (Å)	79.257	80.542	79.335	78.417
<i>c</i> (Å)	54.927	55.535	54.786	54.803
α (°)	90.00	90.00	90.00	90.00
β (°)	105.42	107.69	107.81	112.80
γ (°)	90.00	90.00	90.00	90.00
Resolution (Å) ^a	20-1.80 (1.83-1.80)	20-2.37 (2.41-2.37)	20-2.17 (2.21-2.17)	20-2.42 (2.42-2.46)
<i>R</i> _{merge} ^b (%)	0.068 (0.347)	0.105 (0.485)	0.095 (0.476)	0.101 (0.544)
<i>I</i> / σ	26.4 (2.89)	15.7 (2.30)	22.8 (2.18)	17.7 (1.96)
Completeness (%)	100.0 (100.0)	100.0 (100.0)	100.0 (99.8)	99.9 (99.1)
Redundancy	4.7 (4.1)	4.4 (4.2)	5.4 (4.3)	4.6 (4.0)
Refinement				
<i>R</i> _{work} ^c / <i>R</i> _{free} ^d (%)	20.5/23.6	20.1/25.9	20.2/25.6	20.0/24.3
Unique reflections	41,437	17,394	23,644	16,369
Mean B factor (Å ²)				
Protein	24.29	29.41	39.48	42.65
Ligand	25.35	36.79	36.33	44.28
Solvent	27.48	31.66	37.64	40.01
Ramachandran plot				
Most favored (%)	97.2	98.1	95.7	96.9
Add. ^e allowed (%)	2.8	1.9	4.3	3.1
r.m.s.d.				
Bond lengths (Å)	0.004	0.004	0.004	0.004
Bond angles (°)	0.822	1.044	1.130	1.120

^a Values in parentheses are for the highest resolution shell.

^b $R_{\text{merge}} = \sum |I - \langle I \rangle| / \sum I$ where *I* is the integrated intensity of a given reflection.

^c $R_{\text{work}} = \sum |F(\text{obs}) - F(\text{calc})| / \sum F(\text{obs})$.

^d $R_{\text{free}} = \sum |F(\text{obs}) - F(\text{calc})| / \sum F(\text{obs})$, calculated using 5% of the data.

^e Additionally.

large roll angle induced by the Pt-GG adduct destacks the two guanine bases. The most striking feature of the Pt-GG·dCTP*-Mg²⁺ structure is that, despite the large roll angle, both the 3'-dG and 5'-dG of the Pt-GG form Watson-Crick base pairing with the primer terminus dC and the incoming dCTP*, respectively. The primer terminus and the replicating base pairs have large propeller twist angles (22° and 17°, respectively), which promote the accommodation of the bulky Pt-GG lesion with a relaxed conformation in the pol β active site while retaining Watson-Crick base pairing. To base pair with the templating 5'-dG, the incoming nucleotide does not stack with the primer terminus. The platinum is positioned near N7 of the 5'-dG found in the GG ternary complex (Fig. 3D), pushing the templating dG of the Pt-GG lesion toward the minor groove. Tyr-271 and Arg-283, which typically interact with the minor groove edges of the primer terminus and the templating base, respectively, in the pol β structure with correct insertion (22), do not engage in the minor groove interaction (Fig. 3C). The primer terminus 3'-OH is 3.3 Å away from the P α of the incoming dCTP* and is aligned with the P α of dCTP* at an angle of ~160° for the nucleotidyl transfer reaction. The Pt-GG·dCTP*-Mg²⁺ complex shows the presence of the two active site metal ions, but the catalytic carboxylate Asp-256 is not coordinated to the catalytic metal ion (3.4 Å), which will decrease the insertion efficiency of dCTP opposite the Pt-GG lesion. Hence, the Pt-GG·dCTP*-Mg²⁺ complex structure with a semiopen protein conformation explains why insertion opposite the templating 5'-dG of the Pt-GG lesion is much less efficient than the dCTP insertion opposite unmodified dG. Taken together, the Pt-GG·dCTP*-Mg²⁺ structure provides mechanistic insights

into the accurate yet inefficient nucleotide incorporation opposite the Pt-GG lesion by pol β .

The Pt-GG·dCTP*-Mg²⁺ structure with a semiopen protein conformation most likely represents a ground state that requires a further conformational change to adopt a catalytically favorable conformation. To gain further insight into how pol β inserts dCTP opposite the 5'-dG of the Pt-GG lesion, we determined a ternary structure of the Pt-GG·dCTP* complex in the presence of the active site Mn²⁺, which has been shown to increase the insertion efficiency for various DNA polymerases (23, 31, 36). The Pt-GG·dCTP*-Mn²⁺ structure, refined to 2.4-Å resolution, is substantially different from the Pt-GG·dCTP*-Mg²⁺ structure (r.m.s.d. = 1.418 Å; Fig. 4A) and is quite similar to the GG·dCTP* ternary structure (r.m.s.d. = 0.672 Å). In the Mn²⁺-bound structure, Asp-256 is now coordinated to the catalytic metal ion (2.3 Å), completing the coordination of the catalytic metal ion. In contrast to the Pt-GG·dCTP*-Mg²⁺ structure, the protein adopts a nearly closed or slightly open conformation (Fig. 4B). In particular, the α -helix N shifts toward the nascent base pair ~2.6–4.2 Å from the position observed in the Pt-GG·dCTP*-Mg²⁺ structure (Fig. 4D), sandwiching the replicating base pair between the primer terminus base pair and the α -helix N. The conformational reorganization of α -helix N triggers an upstream shift (~1.5 Å) of the template: primer duplex DNA including the replicating and the primer terminus base pairs but does not induce any significant conformational change of the Pt-GG adduct (Fig. 4D). As observed in the Pt-GG·dCTP*-Mg²⁺ structure, the roll angle for the Pt-GG base pairs is ~60°, and both guanines of the Pt-GG engage in Watson-Crick base pairing with the primer terminus dC and




FIGURE 3. **Structure of the Pt-GG·dCTP*·Mg²⁺ ternary complex (Protein Data Bank code 4TUR).** *A*, close-up view of the Pt-GG lesion in the pol β :Pt-GG·Mg²⁺ complex. Platinum and NH₃ are shown in gray and blue spheres, respectively. *B*, a 2F_o - F_c electron density map contoured at 1 σ around the primer terminus and the replicating base pairs of the Pt-GG lesion. *C*, close-up view of the active site of the Pt-GG·Mg²⁺ complex. The three catalytic aspartates (Asp-190, Asp-192, and Asp-256) and the minor groove-interacting amino acids (Tyr-271, Asn-279, and Arg-283) are indicated. *D*, overlay of the active sites of the Pt-GG·dCTP*·Mg²⁺ (multicolored) and the unmodified GG·dCTP*·Mg²⁺ (white) ternary structures. *E*, overlay of the overall structures of the Pt-GG·dCTP*·Mg²⁺ complex (multicolored; Protein Data Bank code 4TUR) and the unmodified GG·dCTP*·Mg²⁺ complex (white; Protein Data Bank code 4TUQ).

the incoming nucleotide dCTP*. The propeller twist angles for the primer terminus and the nascent base pairs (17° and 3°, respectively) are smaller than those observed in the Pt-GG·dCTP*·Mg²⁺ structure (22° and 17°, respectively). The non-stacked conformation of the Pt-GG lesion appears to prevent the formation of the fully closed protein conformation (Fig. 4*E*) and the engagement of Tyr-271 and Arg-283 in the minor groove edge interaction. The primer terminus 3'-OH is 3.6 Å away from the P α of the incoming nucleotide, which is poised for the nucleotidyl transfer reaction. Taken together, the Pt-GG·dCTP*·Mn²⁺ structure suggests that the pol β catalysis across the Pt-GG lesion may occur through a "semiclosed" protein conformation, which is suboptimal for nucleotidyl transfer.

To evaluate the effect of the active site metal ion on the efficiency of dCTP insertion opposite the Pt-GG lesion, we determined kinetic parameters for dCTP incorporation opposite the templating dG and Pt-GG (Table 2). In the presence of the active site Mg²⁺, the relative efficiency for the dCTP insertion opposite the Pt-GG was ~90-fold lower than that opposite dG, which is consistent with the Pt-GG·dCTP*·Mg²⁺ structure with the semiopen conformation and the incomplete active site

metal ion coordination. The substitution of Mn²⁺ for Mg²⁺ increased the relative efficiency 8-fold, which is consistent with the Pt-GG·dCTP*·Mn²⁺ structure with the nearly closed conformation and the complete active site metal ion coordination. Mn²⁺ is known to be mutagenic (25, 37) and has been shown to increase the misincorporation rate and replication infidelity of various DNA polymerases (32, 33).

Comparison of the pol β :Pt-GG structures with other DNA polymerase:Pt-GG structures reveals that the replication across the 5'-dG of the Pt-GG adduct by the X-family DNA polymerase and the Y-family DNA polymerase occurs through distinct mechanisms. Whereas the conformation of a pol η :Pt-GG·dCTP·Mg²⁺ ternary complex and the normal pol η ternary complexes are similar (r.m.s.d. = 0.3–0.4 Å) (17), the conformations of the pol β :Pt-GG·dCTP·Mg²⁺ ternary complex and the pol β :GG·dCTP·Mg²⁺ ternary complex are dissimilar (r.m.s.d. = 1.396 Å), which partially explains why pol η is more efficient at bypassing the Pt-GG than pol β . The structural comparison also reveals that the conformations of the Pt-GG adduct in the complexes of the Y-family DNA polymerases pol η (17) and Dpo4 (18) are significantly different from that of the

Pol β Catalysis across the Major Cisplatin-DNA Adduct




FIGURE 4. Structure of the pol β :Pt-GG-dCTP*-Mn $^{2+}$ ternary complex (Protein Data Bank code 4TUS). *A*, overall structure of the Pt-GG-dCTP*-Mn $^{2+}$ ternary complex. *B*, overlay of the Pt-GG-dCTP*-Mg $^{2+}$ (white) and the Pt-GG-dCTP*-Mn $^{2+}$ (cyan) structures. *C*, close-up view of the active site region of the Pt-GG-dCTP*-Mn $^{2+}$ structure. *D*, overlay of the active site region of the Pt-GG-dCTP*-Mg $^{2+}$ (white) and the Pt-GG-dCTP*-Mn $^{2+}$ (multicolored) structures. *E*, comparison of the unmodified GG-dCTP*-Mg $^{2+}$ (yellow) and the Pt-GG-dCTP*-Mn $^{2+}$ (multicolored) structures.

TABLE 2

Steady-state kinetic parameters for dCTP insertion opposite the templating dG by pol β

Template-dCTP	Metal ion	K_m	k_{cat}	k_{cat}/K_m	f^a
		μM	10^{-3} s^{-1}	$10^{-3} \text{ s}^{-1} \mu\text{M}^{-1}$	
dG-dCTP	Mg $^{2+}$	0.67 ± 0.03	164.30 ± 6.65	245.2	1
Pt-GG-dCTP	Mg $^{2+}$	5.22 ± 1.01	15.76 ± 1.24	3.0	1.2×10^{-2}
Pt-GG-dCTP	Mn $^{2+}$	1.14 ± 0.05	27.60 ± 1.62	24.2	9.9×10^{-2}

$$^a f = (k_{cat}/K_m)_{\text{Pt-GG-dCTP}} / (k_{cat}/K_m)_{\text{dG-dCTP}}$$

X-family DNA polymerase pol β (Fig. 5). The roll angles for the Pt-GG base pairs in the *Sulfolobus solfataricus* Dpo4 ($\sim 20^\circ$) and human pol η ($\sim 30^\circ$) complexes are smaller than that in the pol β complex ($\sim 60^\circ$), and the distance between N2(5'-dG) and N2(3'-dG) of the Pt-GG lesion for the Dpo4 (4.6 Å) and pol η (5.2 Å) structures is shorter than that for the pol β structure (7.3 Å). In the Y-family DNA polymerase:Pt-GG complex structures, the incoming nucleotide stacks with the primer terminus, which is in contrast to the pol β :Pt-GG complex structures. The conformational differences in the Pt-GG lesions of the X-family and Y-family DNA polymerases appear to stem from the difference in the local environment of the Pt-GG lesion. In the case of the Y-family DNA polymerase, the Pt-GG lesion resides in an open cleft created by the finger domain and the polymerase-

associated domain (also known as little finger) (19). The finger domain interacts with the replicating base pair, and the polymerase-associated domain interacts with the phosphate backbone of the templating Pt-GG lesion, thereby promoting the stacked Pt-GG conformation with a relatively small roll angle in the active site of the enzyme. In the case of the X-family DNA polymerase pol β , which lacks the polymerase-associated domain, the templating Pt-GG lesion does not experience any significant geometric constraints imposed by the protein. In addition, whereas the finger domains of pol η and Dpo4 are relatively rigid, the α -helix N in the finger domain of pol β is flexible, which enables the pol β active site to accommodate the Pt-GG cross-link with the relaxed conformation and a large roll angle.

In summary, our studies provide the structural basis for the mechanism by which pol β performs the accurate but slow replication across the major cisplatin-DNA adduct. Pol β accommodates the bulky templating Pt-GG lesion within its active site without any steric hindrance and allows the formation of Watson-Crick base pairing between the Pt-GG and the incoming dCTP, thereby accurately bypassing the Pt-GG lesion. When complexed with the templating Pt-GG, pol β adopts a catalytically suboptimal conformation, resulting in the slow replication

Pol β Catalysis across the Major Cisplatin-DNA Adduct




FIGURE 5. **Structural comparison of the polymerase:Pt-GG-dCTP complexes.** A, structure of Dpo4 in complex with the Pt-GG-containing DNA. The finger domain and the polymerase-associated domain (PAD) are shown. The distance between N2(5'-dG) and N2(3'-dG) of the Pt-GG lesion is indicated. B, structure of human pol η in complex with the Pt-GG DNA. C, structure of pol β in complex with the Pt-GG DNA in the presence of the active site Mn $^{2+}$. The α -helix N that interacts with the replicating base pair is shown.

across the Pt-GG adduct. Overall, the pol β :Pt-GG-dCTP* complex structures presented here may contribute to understanding of the mechanism of the potential pol β -mediated cisplatin resistance in pol β -overexpressing cancer cells.

Acknowledgments—Instrumentation and technical assistance for this work were provided by the Macromolecular Crystallography Facility with financial support from the College of Natural Sciences, the Office of the Executive Vice President and Provost, and the Institute for Cellular and Molecular Biology at the University of Texas at Austin. The Berkeley Center for Structural Biology is supported in part by the National Institute of General Medical Sciences. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences of the United States Department of Energy under Contract DE-AC02-05CH11231.

REFERENCES

- Jung, Y., and Lippard, S. J. (2007) Direct cellular responses to platinum-induced DNA damage. *Chem. Rev.* **107**, 1387–1407
- Rabik, C. A., and Dolan, M. E. (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. *Cancer Treat. Rev.* **33**, 9–23
- Chaney, S. G., Campbell, S. L., Bassett, E., and Wu, Y. (2005) Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. *Crit. Rev. Oncol. Hematol.* **53**, 3–11
- Xie, K., Doles, J., Hemann, M. T., and Walker, G. C. (2010) Error-prone translesion synthesis mediates acquired chemoresistance. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 20792–20797
- Vaisman, A., and Chaney, S. G. (2000) The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase β . *J. Biol. Chem.* **275**, 13017–13025
- Hoffmann, J. S., Pillaire, M. J., Maga, G., Podust, V., Hübscher, U., and Villani, G. (1995) DNA polymerase β bypasses *in vitro* a single d(GpG)-cisplatin adduct placed on codon 13 of the *HRAS* gene. *Proc. Natl. Acad. Sci. U.S.A.* **92**, 5356–5360
- Srivastava, D. K., Husain, I., Arteaga, C. L., and Wilson, S. H. (1999) DNA polymerase β expression differences in selected human tumors and cell lines. *Carcinogenesis* **20**, 1049–1054
- Canitrot, Y., Frechet, M., Servant, L., Cazaux, C., and Hoffmann, J. S. (1999) Overexpression of DNA polymerase β : a genomic instability enhancer process. *FASEB J.* **13**, 1107–1111
- Canitrot, Y. (2000) Nucleotide excision repair DNA synthesis by excess DNA polymerase β : a potential source of genetic instability in cancer cells. *FASEB J.* **14**, 1765–1774
- Bergoglio, V., Canitrot, Y., Hogarth, L., Minto, L., Howell, S. B., Cazaux, C., and Hoffmann, J. S. (2001) Enhanced expression and activity of DNA polymerase β in human ovarian tumor cells: impact on sensitivity towards antitumor agents. *Oncogene* **20**, 6181–6187
- Canitrot, Y., Cazaux, C., Fréchet, M., Bouayadi, K., Lesca, C., Salles, B., and Hoffmann, J. S. (1998) Overexpression of DNA polymerase β in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 12586–12590
- Kraker, A. J., and Moore, C. W. (1988) Elevated DNA polymerase β activity in a cis-diamminedichloroplatinum(II) resistant P388 murine leukemia cell line. *Cancer Lett.* **38**, 307–314
- Horton, J. K., Srivastava, D. K., Zmudzka, B. Z., and Wilson, S. H. (1995) Strategic down-regulation of DNA polymerase β by antisense RNA sensitizes mammalian cells to specific DNA damaging agents. *Nucleic Acids Res.* **23**, 3810–3815
- Boudsocq, F., Benaim, P., Canitrot, Y., Knibiehler, M., Ausseil, F., Capp, J. P., Bieth, A., Long, C., David, B., and Shevelev, I. (2005) Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase β . *Mol. Pharmacol.* **67**, 1485–1492
- Vaisman, A., Masutani, C., Hanaoka, F., and Chaney, S. G. (2000) Efficient translesion replication past oxaliplatin and cisplatin CpG adducts by human DNA polymerase η . *Biochemistry* **39**, 4575–4580
- Alt, A., Lammens, K., Chiocchini, C., Lammens, A., Pieck, J. C., Kuch, D., Hopfner, K.-P., and Carell, T. (2007) Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase η . *Science* **318**, 967–970
- Zhao, Y., Biertümpfel, C., Gregory, M. T., Hua, Y.-J., Hanaoka, F., and Yang, W. (2012) Structural basis of human DNA polymerase η -mediated chemoresistance to cisplatin. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 7269–7274
- Wong, J. H., Brown, J. A., Suo, Z., Blum, P., Nohmi, T., and Ling, H. (2010) Structural insight into dynamic bypass of the major cisplatin-DNA adduct by Y-family polymerase Dpo4. *EMBO J.* **29**, 2059–2069
- Ummat, A., Rechkoblit, O., Jain, R., Roy Choudhury, J., Johnson, R. E., Silverstein, T. D., Buku, A., Lone, S., Prakash, L., and Prakash, S. (2012) Structural basis for cisplatin DNA damage tolerance by human polymerase η during cancer chemotherapy. *Nat. Struct. Mol. Biol.* **19**, 628–632
- Reissner, T., Schneider, S., Schorr, S., and Carell, T. (2010) Crystal structure of a cisplatin-(1,3-GTG) cross-link within DNA polymerase η . *Angew. Chem. Int. Ed. Engl.* **49**, 3077–3080
- Wang, D., Hara, R., Singh, G., Sancar, A., and Lippard, S. J. (2003) Nucleotide excision repair from site-specifically platinum-modified nucleosomes. *Biochemistry* **42**, 6747–6753
- Sawaya, M. R., Prasad, R., Wilson, S. H., Kraut, J., and Pelletier, H. (1997) Crystal structures of human DNA polymerase β complexed with gapped and nicked DNA: evidence for an induced fit mechanism. *Biochemistry* **36**, 11205–11215
- Koag, M. C., Lee, S. (2014) Metal-dependent conformational activation explains highly promutagenic replication across O6-methylguanine by human DNA polymerase β . *J. Am. Chem. Soc.* **136**, 5709–5721
- Vagin, A., and Teplyakov, A. (2010) Molecular replacement with MOLREP. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 22–25
- Pelletier, H., Sawaya, M. R., Wolffe, W., Wilson, S. H., and Kraut, J. (1996) Crystal structures of human DNA polymerase β complexed with DNA: implications for catalytic mechanism, processivity, and fidelity. *Biochemistry* **35**, 12742–12761
- Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2126–2132

Pol β Catalysis across the Major Cisplatin-DNA Adduct

27. Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Pottterton, E. A., Powell, H. R., Read, R. J., Vagin, A., and Wilson, K. S. (2011) Overview of the CCP4 suite and current developments. *Acta Crystallogr. D Biol. Crystallogr.* **67**, 235–242
28. Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., 3rd, Snoeyink, J., Richardson, J. S., and Richardson, D. C. (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res.* **35**, W375–W383
29. Batra, V. K., Beard, W. A., Shock, D. D., Krahn, J. M., Pedersen, L. C., and Wilson, S. H. (2006) Magnesium-induced assembly of a complete DNA polymerase catalytic complex. *Structure* **14**, 757–766
30. Chamberlain, B. T., Batra, V. K., Beard, W. A., Kadina, A. P., Shock, D. D., Kashemirov, B. A., McKenna, C. E., Goodman, M. F., and Wilson, S. H. (2012) Stereospecific formation of a ternary complex of (S)- α,β -fluoromethylene-dATP with DNA pol β . *Chem. Bio. Chem.* **13**, 528–530
31. Freudenthal, B. D., Beard, W. A., Shock, D. D., and Wilson, S. H. (2013) Observing a DNA polymerase choose right from wrong. *Cell* **154**, 157–168
32. Batra, V. K., Beard, W. A., Shock, D. D., Pedersen, L. C., and Wilson, S. H. (2008) Structures of DNA polymerase β with active-site mismatches suggest a transient abasic site intermediate during misincorporation. *Mol. Cell* **30**, 315–324
33. Tabor, S., Richardson, C. C. (1989) Effect of manganese ions on the incorporation of dideoxynucleotides by bacteriophage T7 DNA polymerase and *Escherichia coli* DNA polymerase I. *Proc. Natl. Acad. Sci. U.S.A.* **86**, 4076–4080
34. Clausen, A. R., Murray, M. S., Passer, A. R., Pedersen, L. C., Kunkel, T. A. (2013) Structure-function analysis of ribonucleotide bypass by B family DNA replicases. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 16802–16807
35. Gregory, M. T., Park, G. Y., Johnstone, T. C., Lee, Y. S., Yang, W., and Lippard, S. J. (2014) Structural and mechanistic studies of polymerase η bypass of phenanthriplatin DNA damage. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 9133–9138
36. Vaisman, A., Ling, H., Woodgate, R., and Yang, W. (2005) Fidelity of Dpo4: effect of metal ions, nucleotide selection and pyrophosphorolysis. *EMBO J.* **24**, 2957–2967
37. El-Deiry, W. S., Downey, K. M., So, A. G. (1984) Molecular mechanisms of manganese mutagenesis. *Proc. Natl. Acad. Sci. U.S.A.* **81**, 7378–7382